Aratana Therapeutics Inc.

Description

• Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, is a fast-growing company headquartered in the greater Kansas City area. Aratana intends to become a pioneer in pet therapeutics by developing, manufacturing and marketing therapeutics that address unmet or underserved medical needs of pets. The Aratana approach to pet therapeutics is built around bringing the best in scientific advances from human science to veterinary medicine.In 2016, we have received FDA approval for three innovative therapeutics: - A prostaglandin receptor antagonist that specifically targets the EP4 receptor to target osteoarthritis pain and inflammation in dogs- A selective ghrelin receptor agonist that mimics ghrelin, the naturally-occurring hunger hormone, to stimulate appetite in dogs- A long-acting, local anesthetic that provides up to 72 hours post-operative pain relief following cranial cruciate ligament surgery in dogsAratana has also received licensure from the USDA for two monoclonal antibodies as aids in the treatment of lymphoma. In addition, Aratana is working on a broad portfolio of other product candidates and continues to seek in-licensing opportunities.
• 

  Headquarters:11400 Tomahawk Creek Parkway Suite 340, Leawood, Kansas, United States

  More
• 

  Phone Number: +1 317-276-9785

• 

  Website: https://www.aratana.com

• 

  Employees:73

• 

  Revenue:$10 - 50M

• 

  Legal Name:Aratana Therapeutics Inc.

• Aratana Therapeutics Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More